17.96
+1.29(+7.74%)
Currency In USD
| Previous Close | 16.67 |
| Open | 16.95 |
| Day High | 18.08 |
| Day Low | 16.81 |
| 52-Week High | 18.08 |
| 52-Week Low | 3.03 |
| Volume | 381,562 |
| Average Volume | 280,666 |
| Market Cap | 478.36M |
| PE | -85.52 |
| EPS | -0.21 |
| Moving Average 50 Days | 13.39 |
| Moving Average 200 Days | 7.06 |
| Change | 1.29 |
If you invested $1000 in Eton Pharmaceuticals, Inc. (ETON) since IPO date, it would be worth $2,873.6 as of February 05, 2025 at a share price of $17.96. Whereas If you bought $1000 worth of Eton Pharmaceuticals, Inc. (ETON) shares 5 years ago, it would be worth $2,645.07 as of February 05, 2025 at a share price of $17.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
GlobeNewswire Inc.
Jan 03, 2025 11:50 AM GMT
Adds an additional commercial and strategic rare disease product to Eton’s portfolioGalzin is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuti
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
GlobeNewswire Inc.
Dec 20, 2024 11:50 AM GMT
Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions DEER PARK, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) --
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
GlobeNewswire Inc.
Dec 17, 2024 11:50 AM GMT
Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE®DEER PARK, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Eto